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Educating pharmacists and the public about the role of over-the-counter
medications in the management of Autism Spectrum Disorders
Abstract
Over-the-counter (OTC) medications are used by various populations as an adjunct to help improve
various aspects of life, such as sleep cycles, disease prevention, and mood. The purpose of this study is
to compile all of the available data from human trials of over-the-counter medications used in patients
with Autism Spectrum Disorders (ASD). OTCs have been used in the treatment of ASD to minimize social
impairments, suppress repetitive behaviors, and enhance quality of sleep to improve daytime behaviors.
Ultimately, the main objectives of this project are to educate pharmacists and the public (both patients
and their families) about the role of over-the-counter medications in the treatment and management of
ASD.
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Educating pharmacists and the public about the role of over-the-counter
medications in the management of Autism Spectrum Disorders
Jillian M. Bankoff, Pharm.D. Candidate; Melinda E. Lull, Ph.D.
St. John Fisher College, Wegmans School of Pharmacy, Rochester, NY

Objective
Over-the-counter (OTC) medications are used by various
populations as an adjunct to help improve various aspects
of life, such as sleep cycles, disease prevention, and mood.
The purpose of this study is to compile all of the available
data from human trials of over-the-counter medications
used in patients with Autism Spectrum Disorders (ASD).
OTCs have been used in the treatment of ASD to minimize
social impairments, suppress repetitive behaviors, and
enhance quality of sleep to improve daytime behaviors.
Ultimately, the main objectives of this project are to
educate pharmacists and the public (both patients and
their families) about the role of over-the-counter
medications in the treatment and management of ASD.

Methods

All clinical trials regarding the use of OTC medications
in ASD were found using PubMed, MedlinePlus, and
primary literature sources found in a public library.
From these trials, data was recorded based on the type
of study, objective, sample size, the behavior that was
measured, and final results and conclusions. After data
collection and compilation, materials will be developed
for dissemination to pharmacists and the public. This
study includes preparing informational pamphlets for
parents and care-takers of children with ASD. General
information on individual products as well as the
clinical data will be included. This information will be
disseminated through local ASD organizations and
medical providers. Additionally, the collected data will
be used to develop a Continuing Education course (CE)
for pharmacists.

OTC/Herbal

Results
Melatonin
• Hypothesized MOA for ASD:
• Reduces the amount of time
it takes to fall asleep and
increases duration of sleep
leading to better daytime
behavior
• Side effects include:
• Nightmares and sleep
walking
• Studied dose ranges:
• 0.75mg-25mg

Vitamin C
• Hypothesized MOA for ASD:
• Improvements in
stereotypical behaviors
including rocking, pacing,
flapping, and whirling
• Side effects include:
• Diarrhea, nausea, cramping,
and nephrolithiasis
• Studied dose:
• 114mg/kg/day

Over-the-Counter
Medications used in ASD*
Vitamin B6 &
Magnesium
• Hypothesized MOA for ASD:
• Improvements in speech and
language and reduction in
hyperexcitability
• Side effects include:
• Nausea, photosensitivity,
peripheral neuropathy
(Vitamin B6), and diarrhea
(Magnesium)
• Studied dose ranges:
• 2.9-30mg/kg (Vitamin B6)
• 1.4-10mg/kg (Magnesium)

Omega-3 Fatty Acids
• Hypothesized MOA for ASD:
• Reduce hyperactivity and
mitigate social impairments
• Side effects include:
• Belching, indigestion, and
diarrhea
• Studied dose ranges:
• 200mg-1.3 g/day

Figure 1: Compiled results of primary literature with OTC use in ASD.
*Note: this is not a comprehensive list of the OTCs studied in the treatment of ASD.

Number of
Studies

Number of
Participants

Outcome

Melatonin

39

879

21 our of 39 studies showed
improved sleep duration.

Vitamin B6 and
Magnesium

21

493

Omega-3 Fatty
Acids

11

339

17 of 21 studies showed some
improvement, whereas
4 showed no significant
difference

Vitamin C

3

37

All studies showed positive
result by reducing severity of
repetitive behaviors.

4 studies showed
insignificance; all other
studies were inconclusive and
require larger sample sizes.

Table 1: Summary table of trials studying OTC use in ASD.

Conclusions

• Data is incomplete based on the number of trials available and the
number of ASD participants. Further studies are required prior to any
definitive conclusions.
• Future directions:
• Summaries and informational pamphlets will be distributed to
caregivers of children with ASD.
• Further research will be conducted on the following
herbals/OTCs: Vitamin B12, Tetrahydrobiopterin, Carnitine, and
Vitamin A
• A CE for pharmacists will be created.
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